Aytu BioPharma确保美国对新的抗抑郁药EXXUATM的权利,为其2025年的发射筹集14 400万美元。 Aytu BioPharma secures U.S. rights to new antidepressant EXXUA™, raising $14.4M for its 2025 launch.

Aytu BioPharma已取得一项独家协议,在美国销售新的抗抑郁药片EXXUATM, 并得到主要保健投资者的支持。 Aytu BioPharma has secured an exclusive agreement to market EXXUA™, a new antidepressant tablet, in the U.S., backed by major healthcare investors. 林业发展局批准的药物表明,在治疗严重的抑郁症,而不产生常见的性副作用方面很有前途。 The FDA-approved drug shows promise in treating major depressive disorder without common sexual side effects. 为了为此提供资金,Aytu正在通过提供股票筹集约1 440万美元,计划在2025年底前启动欧洲铀浓缩公司。 To finance this, Aytu is raising about $14.4 million through a stock offering, planning to launch EXXUA by the end of 2025.